CURRENT AFFAIRS

Detailed explanation-1: -NACOGDOCHES, Texas-Dr. Matibur Zamadar, Stephen F. Austin State University associate professor in the Department of Chemistry and Biochemistry, has received a patent from the U.S. Patent and Trademark Office for his invention regarding therapeutic treatment of bacteria and cancers, and fluorescence diagnosis.

Detailed explanation-2: -The compound, designated EBC-46 and technically called tigilanol tiglate, works by promoting a localized immune response against tumors. The response breaks apart the tumor’s blood vessels and ultimately kills its cancerous cells.

Detailed explanation-3: -Dr. Jung-Mo Ahn, associate professor of chemistry and biochemistry at UT Dallas, synthesized a novel compound called ERX-41 that has shown promise in eliminating cancer cells.

Detailed explanation-4: -The FDA-approved drug, called Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is a new radiation pharmaceutical that is administered through injection or infusion.

Detailed explanation-5: -On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS).